Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection.

Tung-Hung SuChun-Jen LiuTai-Chung TsengShih-Wan ChouChen-Hua LiuHung-Chih YangShang-Ju WuPei-Jer ChenDing-Shinn ChenChi-Ling ChenJia-Horng Kao

Published in: Alimentary pharmacology & therapeutics (2018)

PegIFN/RBV-based antiviral therapy significantly reduced the risk of lymphoma, especially non-Hodgkin's lymphoma; the reduction was mostly among patients <60 years old. Early antiviral therapy for chronic hepatitis C is suggested.

Keyphrases

diffuse large b cell lymphoma
liver fibrosis
stem cells
hodgkin lymphoma
cell therapy
smoking cessation
chemotherapy induced